Mercaptopurine

Search with Google Search with Bing

Information
Drug Name
Mercaptopurine
Description
Entry(CIViC)
23
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
T-cell acute lymphoblastic leukemia NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000675985.1, ENST00000675326.1, ENST00000674860.1, ENST00000674696.1, ENST00000676449.1, ENST00000404739.8, ENST00000675645.1, ENST00000676428.1, ENST00000343289.9 ) NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		D Predictive Supports Resistance Somatic 4 23377281 Detail
T-cell acute lymphoblastic leukemia NT5C2 p.Lys367Gln (p.K367Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) NT5C2 p.Lys367Gln (p.K367Q)
( ENST00000343289.9, ENST00000675645.1, ENST00000676449.1, ENST00000675985.1, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000676428.1, ENST00000404739.8 ) 		D Predictive Supports Resistance Somatic 4 23377281 Detail
T-cell acute lymphoblastic leukemia NT5C2 p.Asp415Ala (p.D415A)
( ENST00000676428.1, ENST00000674860.1, ENST00000676449.1, ENST00000343289.9, ENST00000675985.1, ENST00000674696.1, ENST00000675326.1, ENST00000675645.1, ENST00000404739.8 ) NT5C2 p.Asp415Ala (p.D415A)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		D Predictive Supports Resistance Somatic 4 23377281 Detail
childhood acute lymphocytic leukemia NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000675985.1, ENST00000675326.1, ENST00000674860.1, ENST00000674696.1, ENST00000676449.1, ENST00000404739.8, ENST00000675645.1, ENST00000676428.1, ENST00000343289.9 ) NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		C Predictive Supports Resistance Somatic 2 23377183 Detail
childhood acute lymphocytic leukemia NT5C2 p.Arg246Trp (p.R246W)
( ENST00000676428.1, ENST00000343289.9, ENST00000675985.1, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000404739.8, ENST00000676449.1 ) NT5C2 p.Arg246Trp (p.R246W)
( ENST00000675985.1, ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000676428.1, ENST00000676449.1 ) 		D Predictive Supports Resistance Somatic 4 23377183 Detail
childhood acute lymphocytic leukemia NT5C2 p.Ser453Phe (p.S453F)
( ENST00000676449.1, ENST00000675985.1, ENST00000404739.8, ENST00000675645.1, ENST00000674860.1, ENST00000675326.1, ENST00000674696.1, ENST00000343289.9, ENST00000676428.1 ) NT5C2 p.Ser453Phe (p.S453F)
( ENST00000674860.1, ENST00000675326.1, ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		D Predictive Supports Resistance Somatic 4 23377183 Detail
childhood acute lymphocytic leukemia NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000675985.1, ENST00000675326.1, ENST00000674860.1, ENST00000674696.1, ENST00000676449.1, ENST00000404739.8, ENST00000675645.1, ENST00000676428.1, ENST00000343289.9 ) NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		D Predictive Supports Resistance Somatic 4 23377183 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 T303S PRPS1 T303S D Predictive Supports Resistance Somatic 4 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 L191F PRPS1 L191F D Predictive Supports Resistance Somatic 4 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 D183E PRPS1 D183E D Predictive Supports Resistance Somatic 4 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 K176N PRPS1 K176N D Predictive Supports Resistance Somatic 4 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 N144S PRPS1 N144S D Predictive Supports Resistance Somatic 4 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 S103I PRPS1 S103I D Predictive Supports Resistance Somatic 4 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 S103I PRPS1 S103I D Predictive Supports Resistance Somatic 4 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 S103I PRPS1 S103I D Predictive Supports Resistance Somatic 5 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 A190V PRPS1 A190V D Predictive Supports Resistance Somatic 5 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 A190V PRPS1 A190V D Predictive Supports Sensitivity/Response Somatic 3 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 D139G PRPS1 D139G D Predictive Does Not Support Resistance Somatic 3 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 C77S PRPS1 C77S D Predictive Does Not Support Resistance Somatic 3 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 I72V PRPS1 I72V D Predictive Does Not Support Resistance Somatic 3 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 V53A PRPS1 V53A D Predictive Does Not Support Resistance Somatic 3 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 A87T PRPS1 A87T D Predictive Does Not Support Resistance Somatic 4 25962120 Detail
childhood B-cell acute lymphoblastic leukemia PRPS1 M115T PRPS1 M115T D Predictive Does Not Support Resistance Somatic 4 25962120 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell ... NT5C2 NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000675985.1, ENST00000675326.1, ENST00000674860.1, ENST00000674696.1, ENST00000676449.1, ENST00000404739.8, ENST00000675645.1, ENST00000676428.1, ENST00000343289.9 ) NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell ... NT5C2 NT5C2 p.Lys367Gln (p.K367Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) NT5C2 p.Lys367Gln (p.K367Q)
( ENST00000343289.9, ENST00000675645.1, ENST00000676449.1, ENST00000675985.1, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000676428.1, ENST00000404739.8 ) 		Resitance or Non-Reponse true CIViC Evidence detail
CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell ... NT5C2 NT5C2 p.Asp415Ala (p.D415A)
( ENST00000676428.1, ENST00000674860.1, ENST00000676449.1, ENST00000343289.9, ENST00000675985.1, ENST00000674696.1, ENST00000675326.1, ENST00000675645.1, ENST00000404739.8 ) NT5C2 p.Asp415Ala (p.D415A)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
71 Childhood B-cell acute lymphocytic leukemia rel... NT5C2 NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000675985.1, ENST00000675326.1, ENST00000674860.1, ENST00000674696.1, ENST00000676449.1, ENST00000404739.8, ENST00000675645.1, ENST00000676428.1, ENST00000343289.9 ) NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of NT5C2 R238W ... NT5C2 NT5C2 p.Arg246Trp (p.R246W)
( ENST00000676428.1, ENST00000343289.9, ENST00000675985.1, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000404739.8, ENST00000676449.1 ) NT5C2 p.Arg246Trp (p.R246W)
( ENST00000675985.1, ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000676428.1, ENST00000676449.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of NT5C2 S445F ... NT5C2 NT5C2 p.Ser453Phe (p.S453F)
( ENST00000676449.1, ENST00000675985.1, ENST00000404739.8, ENST00000675645.1, ENST00000674860.1, ENST00000675326.1, ENST00000674696.1, ENST00000343289.9, ENST00000676428.1 ) NT5C2 p.Ser453Phe (p.S453F)
( ENST00000674860.1, ENST00000675326.1, ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of NT5C2 R367Q ... NT5C2 NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000675985.1, ENST00000675326.1, ENST00000674860.1, ENST00000674696.1, ENST00000676449.1, ENST00000404739.8, ENST00000675645.1, ENST00000676428.1, ENST00000343289.9 ) NT5C2 p.Arg375Gln (p.R375Q)
( ENST00000343289.9, ENST00000404739.8, ENST00000674696.1, ENST00000674860.1, ENST00000675326.1, ENST00000675645.1, ENST00000675985.1, ENST00000676428.1, ENST00000676449.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 T303S ... PRPS1 PRPS1 T303S PRPS1 T303S Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 L191F ... PRPS1 PRPS1 L191F PRPS1 L191F Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 D183E ... PRPS1 PRPS1 D183E PRPS1 D183E Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 K176N ... PRPS1 PRPS1 K176N PRPS1 K176N Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 N144S ... PRPS1 PRPS1 N144S PRPS1 N144S Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 S103I ... PRPS1 PRPS1 S103I PRPS1 S103I Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 S103N ... PRPS1 PRPS1 S103I PRPS1 S103I Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 S103T ... PRPS1 PRPS1 S103I PRPS1 S103I Resitance or Non-Reponse true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 A190T ... PRPS1 PRPS1 A190V PRPS1 A190V Resitance or Non-Reponse true CIViC Evidence detail
Treatment with the GART inhibitor, Lometrexol (de ... PRPS1 PRPS1 A190V PRPS1 A190V Sensitivity true CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 D139G ... PRPS1 PRPS1 D139G PRPS1 D139G Resitance or Non-Reponse false CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 C77S i... PRPS1 PRPS1 C77S PRPS1 C77S Resitance or Non-Reponse false CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 I72V i... PRPS1 PRPS1 I72V PRPS1 I72V Resitance or Non-Reponse false CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 V53A i... PRPS1 PRPS1 V53A PRPS1 V53A Resitance or Non-Reponse false CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 A87T i... PRPS1 PRPS1 A87T PRPS1 A87T Resitance or Non-Reponse false CIViC Evidence detail
Lentiviral-mediated overexpression of PRPS1 M115T ... PRPS1 PRPS1 M115T PRPS1 M115T Resitance or Non-Reponse false CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT02828358 Active, not recruiting Phase 2 Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement April 1, 2017 September 22, 2024
NCT05192889 Active, not recruiting Phase 1/Phase 2 Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax August 25, 2022 July 2029
NCT02003222 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia May 19, 2014 December 4, 2024
NCT02143414 Active, not recruiting Phase 2 Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia June 30, 2015 October 23, 2024
NCT02723994 Active, not recruiting Phase 2 A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia September 30, 2016 February 1, 2026
NCT01503632 Active, not recruiting Phase 3 Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission February 21, 2012 December 31, 2029
NCT02112916 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma October 4, 2014 September 22, 2024
NCT00557193 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia January 15, 2008 June 28, 2024
NCT01228331 Active, not recruiting Phase 2/Phase 3 Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL October 2010 December 2024
NCT02688140 Active, not recruiting Phase 3 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia June 2016 January 2025
NCT02101853 Active, not recruiting Phase 3 Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia December 17, 2014 September 22, 2024
NCT02553460 Active, not recruiting Phase 1/Phase 2 Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I January 29, 2016 October 2031
NCT03117751 Active, not recruiting Phase 2/Phase 3 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma March 29, 2017 March 31, 2028
NCT01190930 Active, not recruiting Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma August 9, 2010 March 31, 2028
NCT00408005 Active, not recruiting Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma January 22, 2007 March 7, 2025
NCT03020030 Active, not recruiting Phase 3 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents March 3, 2017 November 2034
NCT02881086 Active, not recruiting Phase 3 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment August 2016 July 2025
NCT02883049 Active, not recruiting Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations February 29, 2012 September 22, 2024
NCT01085617 Active, not recruiting Phase 3 Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia December 2010 December 2025
NCT00005603 Completed Phase 3 Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia March 2000
NCT00005945 Completed Phase 3 Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia June 2000 June 2008
NCT00015873 Completed Phase 3 Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia May 1999 December 2009
NCT00016302 Completed N/A Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia April 2001
NCT00018954 Completed Phase 2 Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma October 1992 October 2002
NCT00022126 Completed Phase 2 Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia November 2002 April 2006
NCT00002514 Completed Phase 3 Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission May 7, 1993
NCT00061945 Completed Phase 1/Phase 2 Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia June 2003 October 2012
NCT00075725 Completed Phase 3 Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia December 29, 2003 March 31, 2021
NCT00089349 Completed Phase 2 Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia July 2004
NCT00096135 Completed N/A Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes November 2004
NCT00103285 Completed Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia April 11, 2005 March 31, 2021
NCT00109837 Completed Phase 2 S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia April 2005 November 2014
NCT00187122 Completed N/A Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma March 1993 June 2004
NCT00198978 Completed Phase 4 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia January 2003 June 2014
NCT00198991 Completed Phase 4 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) April 2003 June 30, 2013
NCT00199004 Completed Phase 4 Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab April 2004 March 2009
NCT00199017 Completed Phase 4 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults April 2004
NCT00199095 Completed Phase 4 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia February 1997 June 2003
NCT00268528 Completed Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission May 30, 2005 June 30, 2020
NCT00276601 Completed Phase 2 Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia October 2004 June 2013
NCT00381680 Completed Phase 3 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia March 2007
NCT00400946 Completed Phase 3 Treatment of Acute Lymphoblastic Leukemia in Children April 2005 June 2019
NCT00430118 Completed Phase 3 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia July 2000 January 2012
NCT00458848 Completed Phase 2 Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia October 2004 March 2014
NCT00482833 Completed Phase 3 Phase III Trial in Acute Promyelocytic Leukemia Patients August 2007 October 17, 2019
NCT00492856 Completed Phase 3 S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia June 1, 2007 May 4, 2016
NCT00494897 Completed Phase 4 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia June 1996 December 2007
NCT00526175 Completed Phase 4 LAL-BR/2001: Study Treatment to Low Risk ALL June 2001 December 2015
NCT00526305 Completed Phase 4 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive January 2000 April 2005
NCT00551460 Completed Phase 2 S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia November 15, 2007 February 5, 2018
NCT00613457 Completed Phase 3 Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia September 2000 July 2006
NCT00671034 Completed Phase 3 Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia July 21, 2008 March 31, 2021
NCT00707083 Completed Phase 3 Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia May 1, 2008 March 1, 2020
NCT00720109 Completed Phase 2/Phase 3 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia July 14, 2008 March 31, 2020
NCT00853008 Completed Phase 4 Treatment of High Risk Adult Acute Lymphoblastic Leukemia January 2003 December 2012
NCT00866307 Completed Phase 1 Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) February 23, 2009 March 31, 2021
NCT00866749 Completed Phase 2 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma September 12, 2006 July 26, 2018
NCT00866918 Completed Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia March 9, 2009 September 30, 2022
NCT00059839 Completed Phase 3 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma November 2003 July 2014
NCT00002618 Completed Phase 3 Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma December 1994 September 2006
NCT00002665 Completed Phase 2 SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia July 1995 December 2003
NCT00002700 Completed Phase 3 Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia August 1995
NCT00002704 Completed Phase 2 Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia January 1996
NCT00002744 Completed Phase 3 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia May 1996 March 2007
NCT00002756 Completed Phase 2 Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia June 1996 March 2012
NCT00002766 Completed Phase 3 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma March 1996 September 2011
NCT00002785 Completed Phase 2 Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia July 1996 March 2007
NCT00002812 Completed Phase 3 Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia September 1996
NCT00003650 Completed Phase 3 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma February 1997 November 2013
NCT00003671 Completed Phase 2 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia December 1998 February 2009
NCT00003700 Completed Phase 2 Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia January 1999 January 2010
NCT00003783 Completed Phase 2 Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia March 1999 March 2007
NCT00003934 Completed Phase 3 Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia June 1999
NCT00004228 Completed Phase 3 Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma June 2000 March 31, 2015
NCT00004688 Completed Phase 2 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms August 1996 July 1998
NCT00005585 Completed Phase 3 Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia April 2000
NCT00005596 Completed Phase 3 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia April 2000 July 2007
NCT01117441 Completed Phase 3 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia June 2010 December 31, 2021
NCT01156883 Completed N/A Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia April 2010 October 31, 2017
NCT01230983 Completed Phase 3 Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma June 1996 October 2004
NCT01256398 Completed Phase 2 Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia December 14, 2010 November 15, 2021
NCT01451515 Completed Phase 2 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma May 25, 2012 May 31, 2022
NCT01700946 Completed Phase 2 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma April 15, 2013 July 24, 2021
NCT02036489 Completed Phase 4 Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia January 2008 December 1, 2019
NCT02177071 Completed Phase 4 A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy October 9, 2015 October 2021
NCT02228772 Completed Phase 1 Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults December 2014 November 2019
NCT02523976 Completed Phase 2 Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia August 1, 2015 December 31, 2021
NCT06390319 Not yet recruiting Phase 2 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) June 2024 December 2033
NCT06317662 Not yet recruiting Phase 2 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia July 31, 2024 December 21, 2027
NCT04440267 Not yet recruiting Phase 2 Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage June 20, 2020 December 20, 2025
NCT06124157 Not yet recruiting Phase 3 A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) July 22, 2024 December 1, 2030
NCT06175702 Not yet recruiting Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL December 25, 2023 December 25, 2030
NCT02205762 Recruiting Phase 2/Phase 3 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis November 2, 2016 July 2025
NCT06336395 Recruiting Phase 2 Ma-Spore ALL 2020 Study March 4, 2020 March 2030
NCT05645718 Recruiting Phase 2 Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia July 14, 2023 December 31, 2029
NCT03007147 Recruiting Phase 3 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia August 8, 2017 September 30, 2027
NCT05157971 Recruiting Phase 1 Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia March 17, 2022 May 22, 2024
NCT05032183 Recruiting Phase 1/Phase 2 Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma February 17, 2022 July 1, 2025
NCT04216524 Recruiting Phase 2 Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm May 29, 2020 December 31, 2026
NCT03959085 Recruiting Phase 3 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy October 31, 2019 March 31, 2030
NCT03914625 Recruiting Phase 3 A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia July 3, 2019 June 30, 2029
NCT02877303 Recruiting Phase 2 Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia November 1, 2016 November 1, 2026
NCT03571321 Recruiting Phase 1 Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia May 28, 2019 September 5, 2027
NCT05303792 Recruiting Phase 2 Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma February 27, 2023 May 2028
NCT00501826 Recruiting Phase 2 Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma July 11, 2007 October 31, 2024
NCT01371630 Recruiting Phase 1/Phase 2 Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia August 26, 2011 December 25, 2025
NCT05959720 Recruiting Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil September 5, 2023 June 2030
NCT05848687 Recruiting Phase 1/Phase 2 TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II November 3, 2023 December 2033
NCT03150693 Suspended Phase 3 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia June 1, 2017 August 2025
NCT04546399 Suspended Phase 2 A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) December 4, 2020 June 30, 2028
NCT02420717 Terminated Phase 2 Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia July 15, 2015 January 20, 2021
NCT03370601 Terminated N/A Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases January 3, 2017 January 2019
NCT00275106 Terminated Phase 3 Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma September 2004 August 2012
NCT02419755 Terminated Phase 2 Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies April 14, 2015 December 31, 2016
NCT02419469 Terminated Phase 2 Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma November 13, 2015 June 22, 2017
NCT03488225 Terminated Phase 2 Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia March 28, 2018 April 2, 2020
NCT03518112 Terminated Phase 2 Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia April 18, 2018 May 27, 2021
NCT00262925 Terminated Phase 2 Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia June 2006 February 2013
NCT00131053 Unknown status Phase 2 Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL) September 2002 September 2011
NCT00002531 Unknown status Phase 2 Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia January 1993
NCT01005758 Unknown status Phase 2 Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia January 2009
NCT00764907 Unknown status Phase 3 Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia November 2002
NCT00558519 Unknown status Phase 2 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia March 12, 2008
NCT00003423 Unknown status Phase 3 Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma May 1995
NCT00003437 Unknown status Phase 3 Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia January 1997
NCT00003728 Unknown status Phase 3 Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma December 1998
NCT03920813 Unknown status Phase 4 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy January 2015 December 2021
NCT02776605 Unknown status Phase 2 Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia June 2016 August 2023
NCT00047268 Unknown status Phase 3 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome July 1998
NCT00131027 Unknown status Phase 3 High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) September 2002 September 2011
NCT00550992 Unknown status N/A Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia January 2006
NCT00343369 Unknown status N/A Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia January 2003
NCT00002701 Unknown status Phase 3 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia October 1995
NCT00019409 Withdrawn Phase 3 Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia October 1999 July 2001
NCT06210750 Withdrawn Phase 2 Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) August 9, 2024 September 22, 2026